Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.

Abstract

MicroRNAs (miRNAs) are short noncoding RNAs that play critical roles in human malignancies and can be used as biomarkers for cancer. Until now, a number of biomarkers for prognosis of glioblastoma (GBM) have been reported in tumor tissues but only a few biomarkers in circulating fluid. Using a custom microarray, we previously identified 19 differentially expressed miRNAs in serum of patients with GBM. In this study, we investigated whether 3 of the 19 miRNAs in serum could be used as prognostic biomarkers for patients with GBM. We first validated the serum levels of 3 candidate miRNAs in an independent cohort of 24 GBM patients and 12 healthy volunteers by real-time quantitative reverse transcription PCR (qRT-PCR), and then evaluated the prognostic value of these miRNAs in a total of 36 GBM patients. The results show that the serum levels of the 3 miRNAs (miR-451a, miR-485-3p and miR-4298) determined by qRT-PCR are significantly different between 24 GBM patients and 12 healthy volunteers (all P <0.05) and are in concordance with the results of microarray analysis. High serum level of miR-451a is correlated with positive tumor O(6)-methylguanine-DNA methyltransferase (MGMT) expression (P = 0.040). Survival analysis showed that low serum miR-485-3p level is associated with poor progression-free survival (PFS) (P < 0.004) and overall survival (OS) (P < 0.023). Furthermore, univariate and multivariate Cox analyses demonstrated that that serum miR-485-3p expression is a significant independent prognostic factor for PFS and OS in GBM patients. In conclusion, serum miR-485-3p level is reduced and might be a potential prognostic biomarker in GBM patients.

• Authors: Zhi-Qiang Wang, Mei-Yin Zhang, Mei-Ling Deng, Nuo-Qing Weng, Hui-Yun Wang, Shao-Xiong Wu
• Journal: PloS one (PLoS One) Vol. 12 Issue 9 Pg. e0184969 ( 2017) ISSN: 1932-6203 [Electronic] United States
• PMID: 28931080 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• MIRN485 microRNA, human
• MicroRNAs
• Tumor Suppressor Proteins
• DNA Modification Methylases
• MGMT protein, human
• DNA Repair Enzymes

Topics

• Adolescent
• Adult
• Aged
• Biomarkers, Tumor (blood, genetics)
• Brain Neoplasms (blood, genetics, mortality, pathology)
• Case-Control Studies
• Combined Modality Therapy
• DNA Modification Methylases (blood)
• DNA Repair Enzymes (blood)
• Female
• Follow-Up Studies
• Gene Expression Regulation, Neoplastic
• Glioblastoma (blood, genetics, mortality, pathology)
• Humans
• Male
• MicroRNAs (blood, genetics)
• Middle Aged
• Neoplasm Staging
• Prognosis
• Real-Time Polymerase Chain Reaction
• Survival Rate
• Tumor Suppressor Proteins (blood)
• Young Adult